These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 19995751)

  • 1. "Go upstream, young man": lessons learned from the p38 saga.
    Hammaker D; Firestein GS
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1(Suppl 1):i77-82. PubMed ID: 19995751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitogen activated protein kinase inhibitors: where are we now and where are we going?
    Sweeney SE; Firestein GS
    Ann Rheum Dis; 2006 Nov; 65 Suppl 3(Suppl 3):iii83-8. PubMed ID: 17038480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
    Medicherla S; Ma JY; Mangadu R; Jiang Y; Zhao JJ; Almirez R; Kerr I; Stebbins EG; O'Young G; Kapoun AM; Luedtke G; Chakravarty S; Dugar S; Genant HK; Protter AA
    J Pharmacol Exp Ther; 2006 Jul; 318(1):132-41. PubMed ID: 16597712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent.
    Miwatashi S; Arikawa Y; Kotani E; Miyamoto M; Naruo K; Kimura H; Tanaka T; Asahi S; Ohkawa S
    J Med Chem; 2005 Sep; 48(19):5966-79. PubMed ID: 16162000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The as-yet unfulfilled promise of p38 MAPK inhibitors.
    Sweeney SE
    Nat Rev Rheumatol; 2009 Sep; 5(9):475-7. PubMed ID: 19710669
    [No Abstract]   [Full Text] [Related]  

  • 6. Kinase inhibitors: a new approach to rheumatoid arthritis treatment.
    Cohen S; Fleischmann R
    Curr Opin Rheumatol; 2010 May; 22(3):330-5. PubMed ID: 20164774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
    Tanaka Y; Maeshima K; Yamaoka K
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i70-4. PubMed ID: 22460142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinase inhibitors: a new class of antirheumatic drugs.
    Kyttaris VC
    Drug Des Devel Ther; 2012; 6():245-50. PubMed ID: 23055694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.
    Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3595-9. PubMed ID: 15177482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAPKs and their relevance to arthritis and inflammation.
    Thalhamer T; McGrath MA; Harnett MM
    Rheumatology (Oxford); 2008 Apr; 47(4):409-14. PubMed ID: 18187523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
    Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
    J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis.
    Westra J; Limburg PC
    Mini Rev Med Chem; 2006 Aug; 6(8):867-74. PubMed ID: 16918493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paeoniflorin inhibits Rho kinase activation in joint synovial tissues of rats with collagen-induced rheumatoid arthritis.
    Zhai W; Ma Z; Wang W; Song L; Yi J
    Biomed Pharmacother; 2018 Oct; 106():255-259. PubMed ID: 29966968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective JAK inhibitors in development for rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.
    MacFarlane LA; Todd DJ
    Int J Rheum Dis; 2014 May; 17(4):359-68. PubMed ID: 24460872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments with investigational Janus kinase inhibitors for rheumatoid arthritis.
    Semerano L; Decker P; Clavel G; Boissier MC
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1355-1359. PubMed ID: 27748152
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
    Nakayamada S; Kubo S; Iwata S; Tanaka Y
    BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of p38: has the fat lady sung?
    Genovese MC
    Arthritis Rheum; 2009 Feb; 60(2):317-20. PubMed ID: 19180514
    [No Abstract]   [Full Text] [Related]  

  • 19. Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety.
    Meier FM; McInnes IB
    Best Pract Res Clin Rheumatol; 2014 Aug; 28(4):605-24. PubMed ID: 25481553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors.
    Bonilla-Hernán MG; Miranda-Carús ME; Martin-Mola E
    Rheumatology (Oxford); 2011 Sep; 50(9):1542-50. PubMed ID: 21622522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.